Milano trial
Asking for Preferences
Could you tell me the full name or the medical area it covers? For example:
- What disease or condition is it studying?
- Any drug or intervention involved?
- Roughly when it was published?
This will help me find the exact trial details for you.
Hdl increasing trails
Searching PubMed
ApoA-I Milano ETC-216 HDL atherosclerosis trial
Searching the Web
Milano trial ApoA-I Milano HDL raising atherosclerosis regression results
Reading File
Reading Article
PMID: 14600188
Searching PubMed
MILANO-PILOT trial ApoA-I Milano coronary atherosclerosis IVUS
Here is a complete breakdown of the Milano Trial and the broader story of HDL-raising therapy:
The ApoA-I Milano Story
Background: The Milano Mutation
In the 1980s, researchers discovered a cluster of residents in Limone sul Garda (a small town near Milan, Italy) who had extremely low HDL-C levels (typically <20 mg/dL) yet showed virtually no cardiovascular disease. The cause was a rare genetic mutation - a single amino acid substitution at position 173 (arginine → cysteine) in ApoA-I, the main structural protein of HDL. This variant was named ApoA-I Milano (ApoA-I^M or AIM).
Despite low HDL, AIM carriers were paradoxically protected, suggesting the quality and function of HDL matters more than simply the quantity.
The Landmark 2003 RCT (Nissen et al., JAMA)
Nissen SE et al., JAMA 2003 (PMID: 14600188)
| Feature | Detail |
|---|---|
| Drug | ETC-216 (recombinant ApoA-I^M / phospholipid complex) |
| Design | Double-blind, placebo-controlled, multicenter RCT |
| Population | 57 patients with acute coronary syndromes (ACS) |
| Intervention | 5 weekly IV infusions of ETC-216 at 15 mg/kg or 45 mg/kg vs placebo |
| Primary endpoint | Change in percent atheroma volume by IVUS |
Key Results:
- ETC-216 group: percent atheroma volume decreased by -1.06% (p = 0.02 vs baseline)
- Placebo group: slight increase of +0.14%
- Absolute reduction in atheroma volume: -14.1 mm³ (4.2% decrease) from baseline (p < 0.001)
- This regression occurred after just 5 weeks of infusions - remarkably rapid
This was the first human trial to demonstrate that an HDL-raising/mimetic infusion could produce measurable plaque regression by IVUS.
MILANO-PILOT Trial (Nicholls et al., JAMA Cardiol, ~2018)
A follow-up trial also used the ApoA-I Milano compound (MDCO-216) in ACS patients with IVUS endpoints. A 2016 study (PMID: 27418968) confirmed that a single infusion of MDCO-216 increased ABCA1-mediated cholesterol efflux and pre-beta-1 HDL - the key metric of reverse cholesterol transport capacity.
Why ApoA-I^M Works Better Than Normal HDL
- Dimeric form: AIM forms cysteine-linked homodimers (AIM/AIM) that persist in blood ~10 days vs 5 days for wild-type ApoA-I
- Enhanced cholesterol efflux: Superior capacity to pull cholesterol from arterial plaque via ABCA1
- Anti-inflammatory effects: Reduces plaque inflammation and promotes stabilization
- Reverse cholesterol transport: More efficient delivery of cholesterol from tissues to liver for excretion
The Broader Picture: Why Simply Raising HDL-C Failed
The Milano story is important because it highlights a key lesson: pharmacologically raising HDL-C numbers does not translate to cardiovascular benefit. Major trials with agents like:
- Niacin (AIM-HIGH, HPS2-THRIVE) - raised HDL but no CV benefit
- CETP inhibitors (torcetrapib, dalcetrapib, evacetrapib, anacetrapib) - raised HDL-C significantly but largely failed to reduce CV events
A meta-analysis of 12 RCTs (n=26,858) showed no significant reduction in mortality or CV outcomes from HDL-raising drugs beyond optimal statin therapy.
The Milano trial shifted thinking from "raise HDL-C" to "improve HDL function and cholesterol efflux capacity."
Current Status
Despite the exciting 2003 results, ETC-216/MDCO-216 development stalled due to:
- Manufacturing complexity of recombinant protein
- Need for IV infusion (not an oral drug)
- High cost
- Larger outcome trials not yet completed
Research continues into HDL-mimetics (CER-001, CSL112) and ApoA-I gene therapy as next-generation approaches.
Summary: The "Milano trial" refers to the landmark Nissen 2003 JAMA RCT showing that 5 weekly IV infusions of recombinant ApoA-I Milano (ETC-216) produced rapid, significant coronary plaque regression in ACS patients - the first human proof that HDL-targeted therapy could reverse atherosclerosis. It remains a landmark in cardiovascular medicine, even though the drug never reached market.
This is a shared conversation. Sign in to Orris to start your own chat.